Gastroesophageal Reflux Disease Market Size, Forecast & Share Analysis 2030

Name: Gastroesophageal Reflux Disease Market Size, Forecast & Share Analysis 2030
Creator: Mordor Intelligence
License: https://www.mordorintelligence.com/privacy-policy

Gastroesophageal Reflux Disease Market Size and Share

Market Overview

Study Period	2019 - 2030
Market Size (2025)	USD 6.39 Billion
Market Size (2030)	USD 7.78 Billion
Growth Rate (2025 - 2030)	8.43% CAGR
Fastest Growing Market	Asia Pacific
Largest Market	North America
Market Concentration	Medium
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Gastroesophageal Reflux Disease Market Summary — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Gastroesophageal Reflux Disease Market Analysis by Mordor Intelligence

The Gastroesophageal Reflux Disease Market size is estimated at USD 6.39 billion in 2025, and is expected to reach USD 7.78 billion by 2030, at a CAGR of 8.43% during the forecast period (2025-2030).

Vonoprazan’s 2024 approval signaled a decisive break from the 30-year dominance of proton pump inhibitors, and potassium-competitive acid blockers (PCABs) are now closing efficacy gaps for refractory patients. Escalating obesity, rapid population aging, and a strong correlation between metabolic syndrome and lower esophageal sphincter dysfunction sustain demand growth. Parallel ESG-driven deprescribing programs are trimming inappropriate PPI use by almost 30% while preserving safety outcomes. On the diagnostic front, AI-enabled high-resolution manometry is redefining workflow efficiency, and LINX magnetic sphincter augmentation offers effective surgical relief for medication-refractory cases. Asia-Pacific’s robust 9.87% CAGR rounds out the growth narrative, underpinned by westernizing diets and expanding healthcare infrastructure.

Key Report Takeaways

By diagnosis, upper endoscopy held 46.76% of the Gastroesophageal Reflux Disease market share in 2024; high-resolution manometry is set to expand at 9.67% CAGR through 2030.
By drug class, proton pump inhibitors commanded 68.52% share of the Gastroesophageal Reflux Disease market size in 2024, whereas PCABs are the fastest-growing category.
By end user, hospitals led with 58.45% revenue share in 2024; home-care settings are projected to grow at a 10.03% CAGR to 2030.
By distribution channel, retail pharmacies & drug stores captured 44.45% of the 2024 Gastroesophageal Reflux Disease market; online pharmacies are advancing at 11.13% CAGR.
By geography, North America retained 35.56% share of the Gastroesophageal Reflux Disease market in 2024, while Asia-Pacific records the fastest regional CAGR at 9.87%.

Global Gastroesophageal Reflux Disease Market Trends and Insights

Drivers Impact Analysis

Driver	% Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Escalating global obesity and ageing population	+2.1%	Global, with highest impact in North America and Europe	Long term (≥ 4 years)
Rising OTC self-medication culture for acid-suppressants	+1.8%	North America & EU, expanding to APAC	Medium term (2-4 years)
Rapid uptake of potassium-competitive acid blockers (PCABs)	+2.3%	Global, led by developed markets	Medium term (2-4 years)
Growing adoption of magnetic sphincter augmentation (LINX)	+0.7%	North America & EU	Long term (≥ 4 years)
AI-enabled high-resolution manometry improving diagnosis	+0.9%	Global, concentrated in tertiary care centers	Medium term (2-4 years)
Corporate ESG push to curb PPI over-prescription	+0.5%	Global, strongest in regulated markets	Short term (≤ 2 years)

Source: Mordor Intelligence

Escalating Global Obesity and Aging Population

Obesity-driven intra-abdominal pressure and age-related motility decline combine to raise GERD prevalence. Asia-Pacific countries such as Japan now confront simultaneous aging and a rise in adolescent obesity, compelling payers to integrate chronic care pathways and early diagnosis strategies. Productivity losses from untreated GERD and comorbidity management strengthen the economic rationale for preventive approaches.^{[1]World Journal of Gastroenterology, “Epidemiology of GERD in Aging and Obese Populations,” wjgnet.com}

Rising OTC Self-Medication Culture for Acid-Suppressants

High out-of-pocket costs in liberalized health systems are pushing consumers toward OTC PPIs and alginates. Pharmacist-led screening has proven effective in preventing duplicate therapy and inappropriate chronic use. Digital symptom-tracking apps tethered to e-commerce platforms are extending self-care while preserving safety oversight. Digital health platforms increasingly integrate with OTC purchases to provide personalized guidance and symptom tracking. The trend accelerates in markets with high healthcare costs, where consumers seek cost-effective alternatives to prescription medications while maintaining treatment efficacy.

Rapid Uptake of Potassium-Competitive Acid Blockers

Vonoprazan’s reversible binding offers faster pH control than irreversible PPIs, achieving 93% healing versus 85% for lansoprazole in pivotal trials. PPI-refractory patients report near-universal healing, and a 10-year exclusivity window protects early revenues while generics prepare pipelines. Geographic expansion remains limited by regulatory approval timelines, creating first-mover advantages in approved markets.

Growing Adoption of Magnetic Sphincter Augmentation (LINX)

LINX delivers 92.7% PPI cessation and 84% quality-of-life improvement with lower complication rates than Nissen fundoplication.^{[2]Journal of the American College of Surgeons, “LINX Magnetic Sphincter Augmentation Outcomes,” journalacs.org} Recent U.S. Medicare coverage decisions are unlocking broader reimbursement, and cost analyses show long-term savings over chronic pharmacotherapy. The technology's appeal lies in its reversibility and preservation of normal anatomy, contrasting with irreversible surgical alternatives. Cost-effectiveness studies support broader adoption, with LINX procedures demonstrating reduced long-term medical expenses compared to continued medical management.

Restraints Impact Analysis

Restraint	% Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Patent cliffs for blockbuster proton pump inhibitors (PPIs) and H2 blockers	-1.4%	Global, strongest in generic-friendly markets	Short term (≤ 2 years)
Increasing FDA safety alerts on chronic PPI use	-0.8%	North America & EU, expanding globally	Medium term (2-4 years)
Slow payer adoption of novel endoscopic therapies	-1.1%	Global, most pronounced in cost-conscious systems	Long term (≥ 4 years)
Supply–chain volatility in key API (omeprazole, esomeprazole)	-0.9%	Global, with highest risk in import-dependent markets	Short term (≤ 2 years)

Source: Mordor Intelligence

Patent Cliffs for Blockbuster PPIs and H2 Blockers

Generic pantoprazole, omeprazole, and esomeprazole have compressed prices as patent shields fall; Protonix exclusivity ends in 2026 and Dexilant in 2030. Branded firms answer with lifecycle tactics, but erosion will deepen in price-sensitive regions where generics can grab share within months of launch.

Increasing FDA Safety Alerts on Chronic PPI Use

Observational studies link chronic PPI exposure to renal injury, fractures, and infection risk, prompting more safety communications and driving physician deprescribing.^{[3]Frontiers in Immunology, “Macrophage Dysfunction with Long-Term PPI Use,” frontiersin.org} The resulting caution dampens volume growth for maintenance-dose PPIs but simultaneously paves the way for newer classes with cleaner safety profiles.

Segment Analysis

By Diagnosis: AI Transforms Traditional Endoscopy

Upper endoscopy continued to dominate with a 46.76% share of the Gastroesophageal Reflux Disease market in 2024, driven by widespread availability and clinician familiarity. Yet AI-powered analysis is streamlining lesion detection and reducing procedure time, forcing endoscopy units to integrate software upgrades. High-resolution manometry is the fastest-growing diagnostic at 9.67% CAGR, fueled by automated pattern recognition that cuts interpretation times. Capsule techniques deliver non-invasive mucosal views for patients unable to tolerate conventional scopes.

Clinical algorithm personalization is the new norm; machine learning now recommends the optimal diagnostic pathway based on symptom clusters, reducing redundant testing. SEA-HRM achieved perfect completion rates in sedation-challenged patients and is likely to convert procedural failures into diagnostic successes. MNBI reference values display regional variation—Vietnamese cohorts show a 1,500-Ohm threshold, stressing the importance of population-specific cut-offs.

Market Share by Diagnosis — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Drug Class: PCABs Challenge PPI Dominance

Proton pump inhibitors still represent 68.52% of the Gastroesophageal Reflux Disease market size in 2024 and grow at 8.79% CAGR, but the metric disguises early PCAB cannibalization in developed markets. H2 antagonists hang on in rapid-relief niches, while antacids and alginates retain relevance for intermittent symptoms. Vonoprazan’s launch has sparked wider PCAB pipelines; linaprazan glurate is advancing for erosive GERD with promising pharmacokinetics.

PCABs provide more stable intragastric pH with less variability than PPIs. Combination regimens pairing alginate barriers with PCABs are under investigation to target multiple acid pathways simultaneously. Generic threats, however, loom as exclusivity windows narrow post-2032.

By End User: Home Care Accelerates Through Telemedicine

Hospitals held 58.45% share of the Gastroesophageal Reflux Disease market in 2024, reflecting their role in advanced diagnostics and refractory case management. Yet virtual care adoption allows stable patients to migrate to home monitoring, pinning a 10.03% CAGR on the home-care segment. Wireless pH capsules paired with smartphone apps supply gastroenterologists with real-time data. A German tertiary center reported telemedicine adherence equal to in-person follow-ups for 35.3% of gastro cases.

Payers incentivize hybrid care to contain costs, and bundled payments now reward reduced readmission rates. Specialty clinics exploit integrated pathways, offering dietitian input and lifestyle coaching alongside pharmacologic management to keep patients out of hospitals.

Market Share by End User — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Distribution Channel: Digital Transformation Accelerates

Retail outlets controlled 44.45% of Gastroesophageal Reflux Disease market transactions in 2024, but online pharmacies are expanding at 11.13% CAGR as convenience and dynamic pricing sway consumer choice. LillyDirect shows how pharma can bypass intermediaries, offering coupon-less discounts directly to patients.

E-commerce ecosystems now tie medication delivery to adherence alerts, and pharmacists conduct video-based medication therapy management to curb inappropriate chronic PPI use. Hospital pharmacies remain critical for IV formulations and controlled introductions of new agents.

Geography Analysis

North America continued to command 35.56% of the Gastroesophageal Reflux Disease market in 2024, benefiting from early PCAB adoption, widespread diagnostic availability, and premium pricing. Clinical guidelines have already integrated vonoprazan for PPI-refractory erosive esophagitis, giving the region a head start in the therapeutic transition. Insurer coverage for LINX and other minimally invasive devices further strengthens procedural revenues.

Europe maintains solid growth on back of structured telehealth programs and ESG-oriented deprescribing protocols. Germany leads digital adoption with reimbursement models supporting remote high-resolution manometry interpretation. EU regulators echo FDA concerns on chronic PPI use, nudging prescribers toward step-down approaches that include H2 antagonists and alginates. Market maturity, however, tempers volume growth for legacy PPIs.

Asia-Pacific is the fastest-growing geography at 9.87% CAGR, driven by rising disposable incomes and urban dietary shifts rich in fat and sugar. China’s local manufacturing base cushions API shortages, while India’s PLI scheme is narrowing its 70% dependency on Chinese intermediates. Japan’s aging yet tech-savvy population fuels telemedicine adoption, whereas South Korea’s high smartphone penetration supports digital adherence programs. Tailored diagnostic thresholds and lower Barrett’s prevalence underscore the need for region-specific management.

Competitive Landscape

The market remains moderately concentrated: top brands such as AstraZeneca, Takeda, and Pfizer still rely on long-standing PPI portfolios, yet innovation now defines competitive leverage. Phathom’s vonoprazan sets a new acid-suppression benchmark, while Zydus acquired rights to market the agent in India under Vault to speed regional uptake. Device innovators add parallel contest: Medtronic’s LINX and Implantica’s RefluxStop widen the solution set for refractory patients.

Patent cliffs threaten incumbent revenue streams, prompting corporate moves like Eisai’s USD 99.6 million divestiture of rabeprazole rights in China to redeploy capital toward higher-growth assets. M&A is reshaping the device arena; Merit Medical’s USD 105 million acquisition of Endogastric Solutions secures access to the EsophyX Z endoscopic fundoplication platform.

AI collaborations are emerging: gastroenterology departments partner with software vendors to refine diagnostic algorithms, and biomarker developers are exploring companion tests to flag likely PPI non-responders. Competitive intensity will hinge on an ability to validate cost-effectiveness under payer scrutiny and to secure supply chain resilience for critical APIs.

Gastroesophageal Reflux Disease Industry Leaders

Johnson & Johnson
Takeda Pharmaceutical Company Limited
SRS Life Sciences
Haleon
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order

Gastroesophageal Reflux Disease Market Concentration — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Need More Details on Market Players and Competitors?

Download PDF

Recent Industry Developments

April 2025: Implantica AG reported German real-world results for the RefluxStop device, emphasizing anatomical restoration without esophageal compression.
March 2025: Eisai sold Chinese rights to rabeprazole (Pariet) to Beijing Peak Biology for JPY 15.7 billion (USD 99.6 million) and kept a milestone clause.
March 2025: Eisai obtained Japanese approval to switch Pariet S 10 mg to OTC status, expanding consumer access.
August 2024: Pfizer secured FDA approval for Protonix I.V. for up to 10 days of adult EE treatment and 7 days in pediatric patients ≥ 3 months.
July 2024: Zydus Lifesciences licensed vonoprazan from Takeda to launch Vault for GERD treatment in India.

Table of Contents for Gastroesophageal Reflux Disease Industry Report

1. Introduction

1.1 Study Assumptions & Market Definition
1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Escalating Global Obesity and Ageing Population
- 4.2.2 Rising OTC Self-Medication Culture for Acid-Suppressants
- 4.2.3 Rapid Uptake of Potassium-Competitive Acid Blockers (PCABs)
- 4.2.4 Growing Adoption of Magnetic Sphincter Augmentation (LINX)
- 4.2.5 AI-Enabled High-Resolution Manometry Improving Diagnosis
- 4.2.6 Corporate ESG Push to Curb PPI Over-Prescription
4.3 Market Restraints
- 4.3.1 Patent Cliffs for Blockbuster Proton Pump Inhibitors (PPIs) and H2 Blockers
- 4.3.2 Increasing FDA Safety Alerts on Chronic PPI Use
- 4.3.3 Slow Payer Adoption of Novel Endoscopic Therapies
- 4.3.4 Supply–Chain Volatility in Key API (Omeprazole, Esomeprazole)
4.4 Regulatory Landscape
4.5 Porter’s Five Forces Analysis
- 4.5.1 Threat of New Entrants
- 4.5.2 Bargaining Power of Buyers
- 4.5.3 Bargaining Power of Suppliers
- 4.5.4 Threat of Substitutes
- 4.5.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

5.1 By Diagnosis
- 5.1.1 Upper Endoscopy
- 5.1.2 Ambulatory pH & Impedance Monitoring
- 5.1.3 Esophageal & High-Resolution Manometry
- 5.1.4 Capsule Endoscopy
- 5.1.5 Others
5.2 By Drug Class
- 5.2.1 Proton Pump Inhibitors (PPIs)
- 5.2.2 H2-Receptor Antagonists
- 5.2.3 Potassium-Competitive Acid Blockers (PCABs)
- 5.2.4 Antacids and Alginates
- 5.2.5 Prokinetics and Others
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Speciality Centers and Clinics
- 5.3.3 Home-Care Settings
5.4 By Distribution Channel
- 5.4.1 Hospital Pharmacies
- 5.4.2 Retail Pharmacies & Drug Stores
- 5.4.3 Online Pharmacies
- 5.4.4 Other Distribution Channel
5.5 By Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East & Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East & Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America

6. Competitive Landscape

6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
- 6.3.1 AstraZeneca
- 6.3.2 Takeda Pharmaceutical Company Limited
- 6.3.3 Haleon
- 6.3.4 Johnson & Johnson Services, Inc.
- 6.3.5 Pfizer Inc.
- 6.3.6 Medtronic
- 6.3.7 Olympus Corporation
- 6.3.8 Reckitt Benckiser
- 6.3.9 Teva Pharmaceutical Industries Ltd.
- 6.3.10 Zydus Lifesciences
- 6.3.11 Glenmark
- 6.3.12 Aurobindo Pharma
- 6.3.13 Eisai Co.
- 6.3.14 Dr Reddy’s Laboratories
- 6.3.15 Hetero Drugs Limited (Camber Pharmaceuticals, Inc.)
- 6.3.16 Perrigo Company
- 6.3.17 Boston Scientific
- 6.3.18 The Procter & Gamble Company
- 6.3.19 Torax Medical
- 6.3.20 SRS Life Sciences
- 6.3.21 Implantica AG

7. Market Opportunities & Future Outlook

7.1 White-space & Unmet-need Assessment

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

Global Gastroesophageal Reflux Disease Market Report Scope

As per the scope of this report, gastroesophageal reflux disease (GERD) is a disorder in which the lower oesophageal sphincter is affected and causes the backflow of contents from the stomach to the esophagus. The major causes of gastroesophageal reflux disease include obesity, smoking, and sedentary lifestyle habits. The Gastroesophageal Reflux Disease Market is Segmented by Diagnosis (Upper Endoscopy, Ambulatory Acid (pH) Probe Test, Esophageal Manometry, and Others), Drug Type (Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Diagnosis	Upper Endoscopy
	Ambulatory pH & Impedance Monitoring
	Esophageal & High-Resolution Manometry
	Capsule Endoscopy
	Others
By Drug Class	Proton Pump Inhibitors (PPIs)
	H2-Receptor Antagonists
	Potassium-Competitive Acid Blockers (PCABs)
	Antacids and Alginates
	Prokinetics and Others
By End User	Hospitals
	Speciality Centers and Clinics
	Home-Care Settings
By Distribution Channel	Hospital Pharmacies
	Retail Pharmacies & Drug Stores
	Online Pharmacies
	Other Distribution Channel

By Geography	North America	United States
		Canada
		Mexico

	Europe	Germany
		United Kingdom
		France
		Italy
		Spain
		Rest of Europe

	Asia-Pacific	China
		Japan
		India
		Australia
		South Korea
		Rest of Asia-Pacific

	Middle East & Africa	GCC
		South Africa
		Rest of Middle East & Africa

	South America	Brazil
		Argentina
		Rest of South America

By Diagnosis

Upper Endoscopy

Ambulatory pH & Impedance Monitoring

Esophageal & High-Resolution Manometry

Capsule Endoscopy

Others

By Drug Class

Proton Pump Inhibitors (PPIs)

H2-Receptor Antagonists

Potassium-Competitive Acid Blockers (PCABs)

Antacids and Alginates

Prokinetics and Others

By End User

Hospitals

Speciality Centers and Clinics

Home-Care Settings

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies & Drug Stores

Online Pharmacies

Other Distribution Channel

By Geography

North America	United States
	Canada
	Mexico
Europe	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe
Asia-Pacific	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific
Middle East & Africa	GCC
	South Africa
	Rest of Middle East & Africa
South America	Brazil
	Argentina
	Rest of South America

Need A Different Region or Segment?

Customize Now

Key Questions Answered in the Report

What is the current size of the Gastroesophageal Reflux Disease market?

The Gastroesophageal Reflux Disease market size is USD 6.39 billion in 2025 and is projected to reach USD 7.78 billion by 2030.

Which drug class holds the largest Gastroesophageal Reflux Disease market share?

Proton pump inhibitors dominate with 68.52% share in 2024, although their growth has slowed as potassium-competitive acid blockers gain momentum.

Why are potassium-competitive acid blockers viewed as game-changing?

PCABs such as vonoprazan provide faster, more consistent acid suppression and have demonstrated superior healing in PPI-refractory patients.

Which region is growing fastest in the Gastroesophageal Reflux Disease market?

Asia-Pacific posts the highest regional CAGR at 9.87%, driven by rising disposable income, dietary westernization, and expanding healthcare access.

How is telemedicine affecting GERD care delivery?

Telemedicine enables up to one-third of follow-up visits to shift to home-based video consultations, supporting rapid growth of the home-care end-user segment.

What is the primary restraint on future PPI sales?

Patent expirations and heightened FDA safety alerts are encouraging generic substitution and deprescribing, curbing long-term PPI revenue growth.